Alzheimer's disease research and development: A call for a new research roadmap

Annals of the New York Academy of Sciences

Volumn 1313, Issue 1, 2014, Pages 1-16

  Feldman, Howard H ^a   Haas, Magali ^b   Gandy, Sam ^c   Schoepp, Darryle D ^d   Cross, Alan J ^e   Mayeux, Richard ^f   Sperling, Reisa A ^g   Fillit, Howard ^h   van de Hoef, Diana L ⁱ   Dougal, Sonya ^j   Nye, Jeffrey S ^k  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b One Mind for Research   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

^d MERCK RESEARCH LABORATORIES   (United States)

^e ASTRAZENECA   (United Kingdom)

^f Taub Institute for Research on Alzheimer's Disease and the Aging Brain and the Gertrude H Sergievsky Center   (United States)

^g HARVARD MEDICAL SCHOOL   (United States)

^h Alzheimers Drug Discovery Foundation   (United States)

ⁱ NEW YORK ACADEMY OF SCIENCES   (United States)

^j NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

^k JANSSEN RESEARCH AND DEVELOPMENT   (United States)

more..

Author keywords

Alzheimer's disease; Dementia; Economics; Epidemiology; Research and development; Therapy; Treatment

Indexed keywords

APOLIPOPROTEIN E4; BAPINEUZUMAB; CHOLINESTERASE INHIBITOR; DONEPEZIL; GALANTAMINE; GAMMA SECRETASE INHIBITOR; GAMMAGARDS; IMMUNOGLOBULIN; IMMUNOGLOBULIN G; MEMANTINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NOOTROPIC AGENT; RIVASTIGMINE; SEMAGACESTAT; SOLANEZUMAB; TARENFLURBIL; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ARTICLE; COGNITIVE DEFECT; DEMENTIA; DISEASE COURSE; DISEASE MODEL; DRUG EFFICACY; DRUG RESEARCH; ENVIRONMENTAL FACTOR; FATIGUE; FOOD AND DRUG ADMINISTRATION; GENETIC RISK; HEALTH CARE COST; HUMAN; INTERPERSONAL COMMUNICATION; INVESTMENT; NONHUMAN; PATENT; PHARMACEUTICAL CARE; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PREDICTIVE VALUE; PREVENTION STUDY; PROBABILITY; PSYCHOLOGIC ASSESSMENT; PUBLIC-PRIVATE PARTNERSHIP; SECONDARY ANALYSIS; SECONDARY PREVENTION; SYSTEMATIC REVIEW; TRANSLATIONAL RESEARCH;

ALZHEIMER'S DISEASE; DEMENTIA; ECONOMICS; EPIDEMIOLOGY; RESEARCH AND DEVELOPMENT; THERAPY; TREATMENT;

ALZHEIMER DISEASE; BIOMEDICAL RESEARCH; COOPERATIVE BEHAVIOR; HUMANS; TRANSLATIONAL MEDICAL RESEARCH;

EID: 84898771737     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1111/nyas.12424     Document Type: Article

References (29)

1. Plassman, B.L, K.M. Langa, G.G. Fisher, et al. 2007. Prevalence of dementia in the United States: The aging, demographics, and memory study. Neuroepidemiology 29(1-2): 125-132.
2. International statistical classification of diseases and related health problems, 10th revision, edition 2010. Geneva, World Health Organization.
3. Schneider, J.A., Z. Arvanitakis, S.E. Leurgans & D.A. Bennett. 2009. The Neuropathology of Probable Alzheimer Disease and Mild Cognitive Impairment. Ann. Neurol. 66(2): 200-208.
4. Woodward, M., I.R.A. Mackenzie, G.Y.R. Hsiung, et al. 2010. Multiple Brain Pathologies in Dementia are Common. Eur. Geriatr. Med. 1(5): 259-265.
5. Dementia: a public health priority. Geneva, World Health Organization. 2012.
6. Pinquart, M. & S. Sorensen. 2006. Helping caregivers of persons with dementia: which interventions work and how large are their effects? Int. Psychogeriatr. 18(4): 577-595.
7. Vitaliano, P.P., J. Zhang & J.M. Scanlan. 2003. Is caregiving hazardous to one's physical health? A meta-analysis. Psychol. Bull. 129(6): 946-972.
8. Schulz, R. & S.R. Beach. 1999. Caregiving as a risk factor for mortality: the Caregiver Health Effects Study. JAMA 282(23): 2215-2219.
9. Raina, P., P. Santaguida, A. Ismaila, et al. 2008. Effectiveness of cholinesterase inhibitors and memantine for treating dementia: evidence review for a clinical practice guideline. Ann. Intern. Med. 148(5): 379-397.
10. Karran, E., M. Mercken & B. De Strooper. 2011. The amyloid cascade hypothesis for Alzheimer's disease: an appraisal for the development of therapeutics. Nat. Rev. Drug Discov. 10(9): 698-712.
11. Sperling, R., S. Salloway, M. Raskind, et al. 2012. A randomized, double-blind, placebo-controlled clinical trial of intravenous bapineuzumab in patients with mild to moderate Alzheimer's disease who are apolipoprotein E ε4 carriers. Presented at: 16th European Federation of Neurological Societies Congress; September 11, Stockholm, Sweden.
12. Eli Lilly and Company. 2012. Lilly announces detailed results of the Phase 3 solanezumab EXPEDITION studies following a presentation of the independent analyses by the Alzheimer's Disease Cooperative Study (ADCS). https://investor.lilly.com/releasedetail.cfm?ReleaseID=711933. October 8, 2012.
13. Eli Lilly and Company. 2012. Lilly provides update on next steps for solanezumab [press release]. https://investor.lilly.com/releasedetail.cfm?ReleaseID=726309. December 12, 2012.
14. http://www.alzforum.org/news/conference-coverage/solanezumab-selected-alzheimers-a4-prevention-trial. January 2013; http://www.alzforum.org/news/research-news/dian-trial-picks-gantenerumab-solanezumab-maybe-bace-inhibitor. October 2012.
15. Jack, C.R. Jr., D.S. Knopman, W.J. Jagust, et al. 2010. Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurol. 9(1): 119-128.
16. Bateman, R.J., C. Xiong, T.L.S. Benzinger, et al. 2012. Clinical and Biomarker Changes in Dominantly Inherited Alzheimer's Disease. N. Engl. J. Med. 367: 795-804.
17. http://www.alzforum.org/news/research-news/solanezumab-benefit-oh-so-small-probably-real?id=3288. October 2012.
18. 6th Conference Clinical Trials on Alzheimer's Disease ABSTRACTS. J. Nutr. Health Aging 17(9): 774-856 [OC16, OC25, P18].
19. Jack, C.R. Jr., H.J. Wiste, S.D. Weigand, et al. 2013. Amyloid-first and neurodegeneration-first profiles characterize incident amyloid PET positivity. Neurology 81(20): 1732-1740.
20. Some hope seen in Negative IVIG Alzheimer Trial. http://www.medpagetoday.com/MeetingCoverage/AAIC/40493. July 16, 2013.
21. Kaufer, D. & S. Gandy. 2009. APOE {epsilon}4 and bapineuzumab: Infusing pharmacogenomics into Alzheimer disease therapeutics. Neurology 73(24): 2052-2053.
22. Sudduth, T.L., A. Greenstein & D.M. Wilcock. 2013. Intracranial injection of Gammagard, a human IVIg, modulates the inflammatory response of the brain and lowers Aβ in APP/PS1 mice along a different time course than anti-Aβ antibodies. J. Neurosci. 33(23): 9684-9692.
23. Gong, B., Y. Pan, W. Zhao, et al. 2013. IVIG immunotherapy protects against synaptic dysfunction in Alzheimer's disease through complement anaphylatoxin C5a-mediated AMPA-CREB-C/EBP signaling pathway. Mol. Immunol. 56(4): 619-629.
24. Cattepoel, S., A. Schaub, M. Ender, et al. 2013. Intravenous immunglobulin binds beta amyloid and modifies its aggregation, neurotoxicity and microglial phagocytosis in vitro. PLoS One 8(5): e63162.
25. Soares, H.D., W.Z. Potter, E. Pickering, et al. 2012. Plasma biomarkers associated with the apolipoprotein E genotype and Alzheimer disease. Arch. Neurol. 69(10): 1310-1317.
26. National Plan to Address Alzheimer's Disease: 2013. Update. http://aspe.hhs.gov/daltcp/napa/NatlPlan2013.pdf
27. Israel, M.A., S.H. Yuan, C. Bardy, et al. 2012. Probing sporadic and familial Alzheimer's disease using induced pluripotent stem cells. Nature 482: 216-220.
28. N. Yahata, M. Asai, S. Kitaoka, et al. 2011. Anti-Aβ Drug Screening Platform Using Human iPS Cell-Derived Neurons for the Treatment of Alzheimer's Disease. PLoS ONE 6(9): e25788.
29. Scott, T.J, A.C. O'Connor, A.N. Link & T.J. Beaulieu 2014. Economic analysis of opportunities to accelerate Alzheimer's disease research and development. Ann. N.Y. Acad. Sci. 1313: 17-34.